Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
ARGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$352.77 - $678.21
Previous CloseN/A
Volume151.62K
Average Volume (3M)402.63K
Market Cap
$35.31B
Enterprise ValueN/A
Total Cash (Recent Filing)$1.45B
Total Debt (Recent Filing)$37.70M
Price to Earnings (P/E)41.8
Beta0.49
Next Earnings
May 08, 2025EPS Estimate
2.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.79
Shares Outstanding60,760,956
10 Day Avg. Volume581,370
30 Day Avg. Volume402,625
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)89.48
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$751.00Price Target Upside24.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
---
Argenx Se News
---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalThe pre-filled syringe formulation of Vyvgart Hytrulo has been approved in the U.S., addressing investor concerns about timing and process related to FDA turmoil.
Market ExpansionThe approval is seen as a best-case scenario for ARGX, enabling Vyvgart penetration into earlier lines of therapy and unlocking additional patient share.
Product ConvenienceThe updated label allows for patient self-administration with the pre-filled syringe, enhancing convenience and expanding potential patient reach.
Bears Say
Net Pricing ConcernsThe shift from medical to pharmacy benefit implies a higher GTN due to rebating, though the company noted the PFS was launching at a 4% higher price than the vial.
Pricing ImpactThe self-administered prefilled syringe formulation will shift patients to Part D, where plan rebates are higher, resulting in a higher gross-to-net discounting.
Pricing StrategyThe shift of Vyvgart from medical to pharmacy benefit as a self-administered product implies a higher gross-to-net due to rebating, although the impact is expected to be offset by the higher launch price of the pre-filled syringe.
---
Ownership Overview
―
Insiders
19.24% Mutual Funds
21.56% Other Institutional Investors
57.77% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARGX FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was $352.77 and its highest was $678.21 in the past 12 months.
What is Argenx Se’s market cap?
Argenx Se’s market cap is $35.31B.
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is May 08, 2025 which is in 22 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Feb 27, 2025. The company reported $11.79 earnings per share for the quarter, beating the consensus estimate of $1.709 by $10.081.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is 2.34.
How many shares outstanding does Argenx Se have?
Argenx Se has 60,760,956 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of $11.79 in its last earnings report, beating expectations of $1.709. Following the earnings report the stock price went up 0.27%.
Which hedge fund is a major shareholder of Argenx Se?
Currently, no hedge funds are holding shares in ARGX
---
Argenx Se Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$751.00 (24.05% Upside)
$751.00 (24.05% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 53.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.01%
12-Months-Change
Fundamentals
Return on Equity
17.33%
Trailing 12-Months
Asset Growth
36.55%
Trailing 12-Months
Company Description
Argenx Se
Argenx SE (ARGX) is a global biotechnology company focused on developing therapies targeting autoimmune diseases and cancer. The company leverages its proprietary antibody engineering technology platform to create innovative treatments aimed at improving patient outcomes. Argenx's core products include efgartigimod, a first-in-class FcRn antagonist for the treatment of autoimmune diseases, and a robust pipeline of other therapeutic candidates in various stages of development.
---
ARGX Company Deck
---
ARGX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical milestones, financial growth, and pipeline expansion, indicating strong momentum. However, there were challenges with exchange losses and an operating loss despite revenue growth. Overall, the positive aspects and future outlook outweigh the negatives.Read More>---
ARGX Stock 12 Month Forecast
Average Price Target
$751.00
▲(24.05% Upside)
Technical Analysis
Best Analysts Covering ARGX
1 Year
1 Year Success Rate
33/38 ratings generated profit
1 Year Average Return
+38.08%
reiterated a buy rating 2 months ago
Copying Derek Archila's trades and holding each position for 1 Year would result in 86.84% of your transactions generating a profit, with an average return of +38.08% per trade.
---